Physician profile
Donald A Selph
NPI 1427163344
$3,350.15
in general payments reported to CMS, 2019-2025
26 companies · $111 in 2025
The $111 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $875 · 2020: $655 · 2021: $798 · 2022: $740 · 2023: $113 · 2024: $58.67 · 2025: $111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $282.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $643.00 | 2022 | |
| Welch Allyn | $643.00 | 2021 | |
| Novo Nordisk INC | $440.39 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $399.76 | 2019-2025 | Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $222.99 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $203.27 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $92.74 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $85.71 | 2020-2021 | |
| Pfizer INC. | $80.09 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $60.37 | 2019-2020 | |
| Abbvie INC. | $57.37 | 2020-2023 | Qulipta |
| Allergan, INC. | $56.69 | 2019-2020 | |
| Lilly USA, LLC | $55.36 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $50.47 | 2019-2020 | |
| Abbott Laboratories | $46.86 | 2023 | Freestyle Libre 2, Freestyle Libre 3 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $40.03 | 2019-2025 | Otezla, Repatha |
| Esperion Therapeutics, INC. | $39.30 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $18.76 | 2019 | |
| Exact Sciences Corporation | $18.00 | 2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $16.68 | 2021 | |
| Genzyme Corporation | $16.28 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.04 | 2022 | |
| Glaxosmithkline, LLC. | $13.70 | 2024 | Arexvy |
| Circassia INC. | $12.37 | 2019 | |
| Eisai INC. | $11.54 | 2020 | |
| Phathom Pharmaceuticals, INC. | $11.38 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Selph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.